In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS sheds more OTC assets in $482m S American option deal with Reckitt

This article was originally published in Scrip

Executive Summary

Reckitt Benckiser (RB) will pay Bristol-Myers Squibb $438 million upfront for the exclusive rights to sell, distribute and market seven over-the-counter BMS medicines in Latin America - primarily Mexico and Brazil - plus a $44 million option fee for the right to purchase the products outright at the end of the three-year OTC marketing agreement's term.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel